Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Regulatory News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

Share Price is delayed by 15 minutes
Get Live Data
46.00    0.00 (0.00%)
Bid:
45.00
Ask:
47.00
Spread: 2.00 (4.444%)
Market Cap: £91.78m
FARN Live PriceLast checked at - London Stock Exchange

Intraday Faron Pharmaceuticals Share Chart

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

16 Apr 2026 15:00

Faron Pharmaceuticals Ltd | Company announcement | April 16, 2026 at 18:00:00 EEST

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuerx
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rightsx
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rightsx
Other (please specify) iii: Dividend payments in kind.
3. Details of person subject to the notification obligation iv
NameTimo Syrj¤l¤
City and country of registered office (if applicable)Monaco
4. Full name of shareholder(s) (if different from 3.) v
NameAcme Investments SPF Sarl
City and country of registered office (if applicable)Luxembourg
5. Date on which the threshold was crossed or reached vi:15.4.2026
6. Date on which issuer notified (DD/MM/YYYY):16.4.2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached7.77%15.509.433
Position of previous notification (ifapplicable)12.69%14.697.112
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type ofsharesISIN code (if possible)Number of voting rights ix% of voting rights
Direct(DTR5.1)Indirect(DTR5.2.1)Direct(DTR5.1)Indirect(DTR5.2.1)
FI40001533095.949.3209.560.1132.98%4.79%
SUBTOTAL 8. A15.509.4337.77%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrumentExpirationdate xExercise/ Conversion Period xiNumber of voting rights that may be acquired if the instrument isexercised/converted.% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrumentExpirationdate xExercise/ Conversion Period xiPhysical or cashSettlement xiiNumber of voting rights% of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark theapplicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xivX
Name xv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
Timo Syrj¤l¤ (Direct)2.98%2.98%
Acme Investments SPF Sarl (Indirect)4.79%4.79%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information Faron share issue during April 2026
Place of completionMonaco
Date of completion16.4.2026
Date   Source Headline
6th Feb 20237:00 amRNSNotice of 2022 Full-Year Results and Annual Report
1st Feb 20233:45 pmRNSHolding(s) in Company
27th Jan 20235:45 pmRNSHolding(s) in Company
27th Jan 20237:00 amRNSResults of Placing
26th Jan 20234:30 pmRNSProposed Issue and Placing
16th Jan 202311:00 amRNSPrice Monitoring Extension
16th Jan 20239:05 amRNSSecond Price Monitoring Extn
16th Jan 20239:00 amRNSPrice Monitoring Extension
16th Jan 20237:00 amRNSTitle: BEXMAB study update
23rd Dec 20227:00 amRNSFaron’s Financial Calendar for 2023
5th Dec 20227:00 amRNSBEXMAB Study Update
1st Dec 20227:00 amRNSFaron Appoints Maija Hollmén PhD as CSO
18th Nov 20224:30 pmRNSAmendment Terms and Conditions with IPF Partners
2nd Nov 20227:00 amRNSFaron Announces Poster Presentation at SITC
31st Oct 20227:00 amRNSBEXMAB Study Update
19th Oct 20229:20 amRNSHolding(s) in Company
18th Oct 202212:30 pmRNSHolding(s) in Company
18th Oct 20227:00 amRNSFaron Announces Melanoma Cohort Data from MATINS
14th Oct 20227:00 amRNSResults of Placing
13th Oct 20225:31 pmRNSProposed Issue and Placing of Shares
22nd Sep 20227:00 amRNSGrant of Options
20th Sep 20227:00 amRNSTop-Line Data on Bexmarilimab Dose Variation
14th Sep 20227:00 amRNSFaron to Host Bexmarilimab Update Webcast
13th Sep 20227:00 amRNSTraumakine Data Presented at MHSR Symposium
7th Sep 20221:00 pmRNSFaron to Present at Upcoming Conferences
25th Aug 20227:00 amRNSFaron Reports 2022 Half-Year Financial Results
8th Aug 20227:00 amRNSNotice of Half-Year Financial Results
7th Jul 20229:45 amRNSResults of EGM
30th Jun 20225:00 pmRNSHolding(s) in Company
28th Jun 20221:47 pmRNSRegistration of New Shares
28th Jun 20227:00 amRNSAnnouncement of Placing
16th Jun 202212:00 pmRNSFaron notice of EGM
15th Jun 20227:00 amRNSFaron Announces Top-Line 12-Month Survival Results
8th Jun 20227:00 amRNSFirst Patient Dosed in Ph I/II BEXMAB Combo Study
1st Jun 20227:00 amRNSExercise of options
30th May 20227:00 amRNSPresentation of Biomarker Analysis at ASCO
16th May 20227:00 amRNSFDA and FIMEA approve BEXMAB study to begin
12th May 20223:50 pmRNSEx Vivo Data Presented at EHA2022 Congress
9th May 20227:00 amRNSMol Cancer Ther Publishes Bexmarilimab Research
4th May 202211:15 amRNSGrant of options
22nd Apr 20221:01 pmRNSBoard Changes
22nd Apr 20221:00 pmRNSResults of AGM
21st Apr 20224:30 pmRNSFaron Presents Melanoma Data at EADO
8th Apr 20223:45 pmRNSManagers’ Transactions
5th Apr 20227:00 amRNSFaron Closes HIBISCUS Trial
25th Mar 20229:00 amRNSNotice of Faron Pharmaceuticals Ltd’s AGM
25th Mar 20227:15 amRNSFaron´s Annual Report 2021 Published
25th Mar 20227:00 amRNSFinancial Statement January 1 to December 31 2021
14th Mar 20227:00 amRNSFaron Publishes Research From INTEREST Trial
9th Mar 20227:00 amRNSPresentation of Biomarker Data at AACR 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.